ProQR Therapeutics
PRQR
57 hedge funds and large institutions have $364M invested in ProQR Therapeutics in 2018 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 6 closing their positions.
383% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 6
68% more funds holding
Funds holding: 34 → 57 (+23)
9.81% more ownership
Funds ownership: 51.49% → 61.3% (+9.8%)
3% less capital invested
Capital invested by funds: $378M → $364M (-$13.2M)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$62.5M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$52.4M |
| 3 |
BlackRock
New York
|
+$12.9M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$9.18M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$60.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$28.1M |
| 3 |
O
OrbiMed
New York
|
-$11M |
| 4 |
Morgan Stanley
New York
|
-$1.69M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.14M |
PRQR Hedge Fund Activity: Q4 2018 in Review
57 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2018, worth a combined $364M — down 3.5% from $378M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PRQR positions and 6 closed out — a net gain of 23 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $62.5M. The largest seller was RTW Investments, cutting an estimated $60.4M.
- 57 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2018, up from 34 in Q3 2018.
- Funds reported $364M of ProQR Therapeutics stock for Q4 2018, down 3.5% quarter-over-quarter.
- 29 funds opened new ProQR Therapeutics positions in Q4 2018 and 6 closed out, a net change of +23 holders.
- The largest ProQR Therapeutics buyer in Q4 2018 was Goldman Sachs, an estimated $62.5M added.
- The largest ProQR Therapeutics seller in Q4 2018 was RTW Investments, an estimated $60.4M sold.
Based on aggregated 13F filings for Q4 2018.